Hearing Loss and Tinnitus During Fluvoxamine Treatment: A Case Report

被引:0
作者
Gundogar, Duru [1 ]
Derekoy, Fevzi Sefa [2 ]
Yilmaz, Deniz [2 ]
机构
[1] Suleyman Demirel Univ, Sch Med, Dept Psychiat, TR-32200 Isparta, Turkey
[2] Afyon Kocatepe Univ, Sch Med, Dept Otolaryngol, Afyon, Turkey
来源
KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY | 2009年 / 19卷 / 01期
关键词
Fluvoxamine; serotonin reuptake inhibitors; hearing loss; tinnitus; SEROTONIN REUPTAKE INHIBITORS; AUDITORY-CORTEX; SIGMA-RECEPTORS; RAT-BRAIN; FLUOXETINE; SUBTYPES;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fluvoxamine is a widely prescribed selective serotonin reuptake inhibitor (SSRI). Although it is known that serotonin constitutes an important network in the hearing process and there are recent studies investigating the effects of serotonin and SSRI's on the auditory functions, its exact role is not well characterized. In this paper we present a case with hearing loss and tinnitus which developed during fluvoxamine treatment and disappeared after discontinuation of fluvoxamine. A 54-year-old female patient with major depression had complaints about tinnitus and hearing loss in her right ear during fluvoxamine treatment. There were no significant abnormalities in her medical history, she was not taking any other medications, and ear-nose-throat examination was within normal limits. Audiometry revealed mixed hearing loss and transient otoacoustic emission (TOAE) recordings revealed a low reproducibility and low signal to noise ratio in the right ear. The control investigations after discontinuation of fluvoxamine revealed that the auditory functions were restored. The hearing loss in our patient might be due to the interference of fluvoxamine with facial nerve functioning or the effects of serotonin on the auditory sensorineural transmission. This case was considered to be noteworthy to publish, in order to increase clinicians' awareness
引用
收藏
页码:59 / 63
页数:5
相关论文
共 18 条
[1]   Mechanisms of tinnitus [J].
Baguley, DM .
BRITISH MEDICAL BULLETIN, 2002, 63 :195-212
[2]   The role of sigma receptors in depression [J].
Bermack, JE ;
Debonnel, G .
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2005, 97 (03) :317-336
[3]   [H-3]1,3-di(2-tolyl)guanidine and [H-3](+)pentazocine binding sites in the rat brain: Autoradiographic visualization of the putative sigma(1) and sigma(2) receptor subtypes [J].
Bouchard, P ;
Quirion, R .
NEUROSCIENCE, 1997, 76 (02) :467-477
[4]   Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview [J].
Carrasco, JL ;
Sandner, C .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2005, 59 (12) :1428-1434
[5]   Serotonin reuptake inhibitors in auditory processing disorders in elderly patients: Preliminary results [J].
Cruz, OLM ;
Kasse, CA ;
Sanchez, M ;
Barbosa, F ;
Barros, FA .
LARYNGOSCOPE, 2004, 114 (09) :1656-1659
[6]  
CUNNINGHAM M, 1990, AM J PSYCHIAT, V147, P947
[7]   Systematic review and guide to selection of selective serotonin reuptake inhibitors [J].
Edwards, JG ;
Anderson, I .
DRUGS, 1999, 57 (04) :507-533
[8]  
FEIGHNER JP, 1985, J CLIN PSYCHIAT, V46, P369
[9]  
*GLAX SMITH KLIN, 2002, PROD INF PAX
[10]   Selective serotonin reuptake inhibitors treatment effects on auditory measures in depressed female subjects [J].
Gopal, KV ;
Briley, KA ;
Goodale, ES ;
Hendea, OM .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 520 (1-3) :59-69